Navigation Links
Alfacell Announces ONCONASE(R) Purchase and Supply Agreement with Scientific Protein Laboratories

SOMERSET, N.J., Jan. 18 /PRNewswire-FirstCall/ -- Alfacell Corporation (Nasdaq: ACEL) today announced that it has entered into a purchase and supply agreement with Scientific Protein Laboratories LLC (SPL) for the commercial production of ONCONASE(R) (ranpirnase). ONCONASE, the company's lead drug candidate, is currently being evaluated as a treatment for unresectable malignant mesothelioma (UMM) in a confirmatory Phase IIIb clinical trial.

"SPL has been involved in the production of ONCONASE from the very first batches," said Kuslima Shogen, chief executive officer of Alfacell. "We have been pleased with the superb performance of the extremely well qualified team at SPL for many years and are confident that the commercial production of ONCONASE is in the right hands. This agreement is another step forward for Alfacell as we plan for the commercialization of ONCONASE."

"We have been very enthusiastic about the Alfacell project from the very beginning," said David Strunce, president and chief executive officer of SPL. "We are impressed by the way that Alfacell has successfully guided their novel product through the development phases, and we are pleased to have the opportunity to continue the collaboration with the Alfacell team into the commercial stage."

About Scientific Protein Labs LLC

For over three decades, Scientific Protein Laboratories (SPL) has been a leading global supplier of high quality active pharmaceutical ingredients (APIs) from natural sources. The company specializes in cGMP biopharmaceutical manufacturing and is among the largest commercial suppliers of Heparin Sodium USP, Pancreatin USP and Pancrelipase USP in serving the pharmaceutical, veterinary and food industries globally. Beyond supplying high quality proprietary APIs, SPL provides contract process development and cGMP manufacturing services, including heparin derivatives, natural products extraction, fermentation and purification. SPL is among a small number of companies that have successful track records in efficient process development, analytical testing, quality assurance and regulatory support required to provide customers with cGMP compliant APIs at all phases of clinical development and straight through to commercial launch.


ONCONASE is a first-in-class product candidate from Alfacell's proprietary ribonuclease (RNase) technology. A natural protein isolated from the leopard frog, ONCONASE has been shown in the laboratory and clinic to target cancer cells while sparing normal cells. ONCONASE triggers apoptosis (natural death of cells) via multiple molecular mechanisms of action.

About Alfacell Corporation

Alfacell Corporation is the first company to advance a biopharmaceutical product candidate that works in a manner similar to RNA interference (RNAi) through late-stage clinical trials. The product candidate, ONCONASE, is an RNase that overcomes the challenges of targeting RNA for therapeutic purposes while enabling the development of a new class of targeted therapies for cancer and other life-threatening diseases. In addition to an ongoing Phase IIIb study in malignant mesothelioma, Alfacell is conducting a Phase I/II trial of ONCONASE in non-small cell lung cancer (NSCLC) and other solid tumors. For more information, visit

Safe Harbor

This press release includes statements that may constitute "forward- looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar expressions. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, uncertainties involved in the outcome of clinical trials for ONCONASE, the company's ability to secure necessary marketing approvals of ONCONASE from regulatory agencies, transitioning from concept to product, uncertainties involving the ability of the company to finance research and development activities, potential challenges to or violations of patents, dependence upon third-party vendors, and other risks discussed in the company's periodic filings with the Securities and Exchange Commission. By making these forward-looking statements, the company undertakes no obligation to update these statements for revisions or changes after the date of this release.

Media and Investor Contact:

David Schull or Wendy Lau

Russo Partners


SOURCE Alfacell Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Alfacell to Host Webinar on RNA Interference-Like Mechanics of RNase Therapeutics on Nov. 29
2. Alfacell to Host Fiscal Fourth Quarter and Year-End 2007 Financial Results Conference Call and Webcast
3. Alfacell to Present at BIO InvestorForum 2007
4. Peptimmune Announces First Close of Series D Private Financing
5. Schering-Plough Announces Sugammadex New Drug Application Filed in Japan
6. Gen-Probe Announces Webcast of Fourth Quarter and Full Year 2007 Earnings Conference Call
7. Vasogen Announces 2007 Year-End Results
8. RSB Spine, LLC Announces First Implantation of the InterPlate(TM) L for the Lumbar Spine
9. Stereotaxis Announces FDA Approval of Its Partnered Magnetic Irrigated Catheter
10. Healthcare Technologies Ltd. (NASDAQ: HCTL) Announces Extension of Letters of Intent to Acquire Majority Interest in Two Ethanol Plants
11. BioSpecifics Technologies Corp. Announces Sale of Stock in Private Placement Offering
Post Your Comments:
(Date:10/8/2015)... 2015   Intrexon Corporation (NYSE: XON ... appointment of Joseph L. Vaillancourt as Senior ... Nimrodi who continues in his role as Head ... to generate sustainable, biologically based solutions to environmental problems. ... held a variety of key roles including, Vice President ...
(Date:10/8/2015)... IRVINE, Calif. , Oct. 8, 2015 ... announced its expansion into the North American market with ... Asia and Europe ... a pioneer of Target Enrichment methodology and sample preparation ... or NGS, facilitates both hereditary and somatic genetic testing ...
(Date:10/8/2015)... 2015  The ALS Association, in partnership with Prize4Life, ... to revolutionize communication technology solutions for people living with ... ALS (amyotrophic lateral sclerosis) is a progressive neurodegenerative disease ... the spinal cord. Eventually, people with ALS lose the ... leads to total paralysis and death within two to ...
(Date:10/8/2015)... , ... October 08, 2015 , ... ... into an exclusive license agreement to develop and commercialize intellectual property rights belonging ... original agreement from February 2009, and affords exclusive worldwide rights to intellectual property ...
Breaking Biology Technology:
... 9, 2011) The brain is a black box. ... much like the inner workings of a computer chip. ... economy of an assembly line, neural circuits are impenetrable ... Department of Neurobiology have developed a technique for unraveling ...
... of Standards and Technology (NIST),have demonstrated an ... mechanical component 1,000 times,more vigorously than ever ... a new tool for processing,information and potentially ... object at the,smallest possible, or quantum, scale. ...
... NEW YORK, March 9, 2011 ... is available in its catalogue: ... and Market Forecasts to 2017 ... Retinopathy Therapeutics - Pipeline Assessment and Market ...
Cached Biology Technology:
(Date:10/7/2015)... , October 8, 2015 ... revenues for Fingerprint Cards (FPC) during third quarter 2015 amounted ... guidance of around 860 MSEK that was communicated 20 August ... a further strengthened delivery capacity and a continued growing demand ... 2015 is estimated to be higher than during the third ...
(Date:10/5/2015)... ) releases the following ... NXTD ), a biometric authentication company focused on the ... ) releases the following market and company update ... authentication company focused on the growing mobile commerce market. ... ) releases the following market and company update ...
(Date:9/30/2015)... , Sept. 30, 2015  The U.S. Court of ... another key ruling in favor of Crossmatch ™, ... fingerprint scanner company Suprema and its U.S. partner Mentalix ... a trade provision that declares it unlawful to engage ... infringing two of Crossmatch,s patents, the 5,900,993 patent and ...
Breaking Biology News(10 mins):
... The Proceedings of the National Academy of Science ... Medicine generated a mouse model exhibiting reduced inflammation. ... transcription factor LITAF (Lipopolysaccharide [LPS]-Induced TNF-Alpha Factor) controls ... better known and studied NF-kB transcriptional regulator. ...
... for insects and other small terrestrial animals by firing ... the water's surface. These water shots were once thought ... discovered new levels of sophistication in the archerfish's hunting ... behavior has evolved. The findings are reported by Thomas ...
... at the University of Rochester may have answered one ... our neurons, which are responsible for our crystal-clear thoughts, ... the November issue of Nature Neuroscience, the Rochester study ... "noisy," signals to represent the ambiguities of the real ...
Cached Biology News:
... Software reads and processes raw ... microarray data for analysis. ... one 2-year license for Feature ... , * one CD-ROM ...
... imported for data analysis , Automatic grid, subgrid ... template assignment , ... Extensive background and signal options to optimize, ... results , ...
... DNA Gel Stain combo offers these benefits: ... products separately Offers a ... Eliminates risks to yourself, the environment ... from 100 bp to >30 kb. UltraPure Agarose is ...
... stocks contained in standard 96-well microtiter plates. ... approximately 5,000 clones per plate. After positive ... the corresponding subplate is screened with a ... well(s). Cells from a positive well are ...
Biology Products: